APELOA PHARMACEUTICAL CO

Apeloa Pharmaceutical’s stock hits a 17.5% dip amid a CRO slump, trading below its 200‑day SMA at ¥19.65. Learn the latest market trends and peer performance.

Apeloa Pharma’s weight‑loss trial shows significant female weight and waist reduction, sparking 2027 launch hopes and investor interest in the obesity market.